Navigation Links
E. coli strains resistant to a common antibiotic

Food contaminated with a strain of drug-resistant E. coli has emerged as a possible new source of urinary tract infections. E. coli is a normal inhabitant of the digestive tract that can cause both intestinal upsets and urinary infections. But while E. coli from bad food is a frequent cause of diarrhoea and other digestive miseries, urinary tract infections were thought until now to result mostly from inadvertent contact with the victim's own feces. Urinary tract infections are common, especially among women, and cause painful and frequent urination. //

The new research found that a single, genetically identical strain was responsible for outbreaks of urinary tract infections among women in California, Michigan and Minnesota. Because the germs are exactly the same, investigators assume they came from the same source, and the most likely such source is food.

The research, conducted at the University of California at Berkeley, was based on analysis of 302 cases. "We were really, really surprised," said researcher Amee R. Manges at Berkeley. "When we looked at these organisms from these various different women, many of them turned out to be the same. We weren't anticipating that."

The researchers looked specifically at infections caused by E. coli strains resistant to a common antibiotic, trimethoprim-sulfamethoxazole, sold as Bactrim or Septra. They found the same strain caused 51 percent of the drug-resistant infections at Berkeley, 38 percent in Michigan and 39 percent in Minnesota.


'"/>




Page: 1

Related medicine news :

1. African HIV strains more resistant to anti HIV drugs
2. Hormone restrains appetite in man
3. Bioengineering production strains - Microbia develops new methods
4. Fluorescent markers to distinguish Trypanosoma brucei strains causing Sleeping Sickness
5. Detection of Weak strains of bird flu virus – Target of European Unio
6. Resistant Influenza strains creates panic in US
7. Multiple infectious disease strains can coexist
8. Threat posed by highly resistant strains of TB
9. African HIV strains more resistant to anti HIV drugs
10. Gene researchers make Malaria-resistant mosquito
11. Vaccine Reduces antibiotic-resistant infections in Children
Post Your Comments:
(Date:5/16/2008)... the lining of the uterus (submucosal) are more li...ne artery embolization (UAE) but usually dont caus..., The study included 49 patients with 140 fibroi...er UAE. The study found that 39 of these were subm...cavity after UAE, said Sachit Verma, MD, lead auth...
(Date:5/16/2008)...ise $38 Million for Life-threatening,Disease, BET...ers in nearly,every state will raise funds for cys...articipating in GREAT STRIDES, the largest nationa...nnounced today., May is National Cystic Fibrosis ...ning genetic disease that causes fatal lung infect...
(Date:5/16/2008)...ational HIV Vaccine Awareness Day, May,18, WASHIN... years into the,AIDS epidemic, someone is newly in...nday, May 18, HIV Vaccine Awareness Day, AIDS Acti...Institute of Allergy and Infectious,Disease (NIAID... everyone,to help end the AIDS epidemic by partici...
(Date:5/16/2008)...re-USNewswire/ -- Emergency Medical,Services Week,...edication,of Pennsylvania,s first responders and e...teers, according to state Secretary of Health Dr. ...fe is Our Mission," emphasizes that no,matter what...to provide,immediate, life-saving care and transpo...
Breaking Medicine News(10 mins):Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2Health News:AIDS Action Urges Everyone to Help End the AIDS Epidemic by Being Part of the Search for an HIV Vaccine 2Health News:PA Secretary of Health Announces 'Emergency Medical Services Week,' May 18 - 24 2
... death toll in the fake drug case in China has sho...heck on pharmaceutical companies//, the state medi...dead from using the fake Armillarisni A injection ...ical Co Ltd, said officials with the Third Hospita...
... U.S. Food and Drug Administration authority is un...y contraception drug as an over-the counter drug//...he FDA has been urged to take an independent, non-...euticals Inc's bid to sell its morning after pill ...
... persons were arrested for allegedly selling fake ...CPMT), which was held at 137 centres across// 17 d...rsons were arrested in Allahabad and another perso... CPMT question papers, which later turned out to b...
...tland: This ain’t funny, but drugs seem to hold ma...ed the alarming rise of drugs among youngsters,// ... labour has come to power. Experts have reiterate... remedy this menace, among children. Neil McKegane...
Other Medicine News:
(Date:5/15/2008)...icacy Clinical Data from Prostate, Colorectal and ...- Company to Hold Investor Event on Sun., June 1 w...f., May 15 /- Poniard,Pharm...ical company focused,on oncology, today announced ...ical trials of picoplatin, in various tumor types ...
(Date:5/15/2008)...nted amount of research reflects depth and breadth...o develop new treatments for ...ighlight impact of Zometa(R), the leading IV, bisp...-stage breast cancer, - Four oral sessions to fea...ibitor of mTOR, including first results of RECORD-...
(Date:5/15/2008)...N.J., May 15 /- Sanofi-aven...that findings from the,landmark ATHENA study showe... the treatment of patients with atrial fibrillatio...ascular hospitalizations or death from any,cause b...meeting the study,primary endpoint. The ATHENA res...
(Date:5/15/2008)...itzerland, May 15 /- Ergonex Pharma t...g Administration (FDA) has,granted orphan drug des...ry,arterial hypertension (PAH). Terguride is curre... trial in Europe., "The FDA,s grant of orphan dru...strengthens our development program by offering re...
Breaking Medicine Technology:Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Positive Results Published Using AtriCure Minimally Invasive Products 1157 1Positive Results Published Using AtriCure Minimally Invasive Products 1157 2Positive Results Published Using AtriCure Minimally Invasive Products 1157 3Positive Results Published Using AtriCure Minimally Invasive Products 1157 4Team Finds 118 Genes That Might Play Role in Cancer 9186 1Team Finds 118 Genes That Might Play Role in Cancer 9186 2Youth Suicide Warnings Are Slowing Antidepressant Sales 9181 1Youth Suicide Warnings Are Slowing Antidepressant Sales 9181 23M Donates Two Full Paint Schemes to American Red Cross for the 2008 NASCAR Sprint Cup Season 9176 13M Donates Two Full Paint Schemes to American Red Cross for the 2008 NASCAR Sprint Cup Season 9176 23M Donates Two Full Paint Schemes to American Red Cross for the 2008 NASCAR Sprint Cup Season 9176 3
... III Study Meets Primary Endpoint in,Rheumatoid Ar...or,Necrosis Factor Treatments -, NUTLEY, N.J., Jul...hat results from the Actemra Radiate (RheumAtoiD,A...fully met its,primary endpoint in patients with mo...led to respond to anti-tumor necrosis factor,treat...
...formation May Correlate with Clinical HbA1c,Reduct... Clinical,Trials --, PALO ALTO, Calif., July 9, 20... announced today that researchers have completed,p...zine increased,glucose stimulated insulin secretio...s using preclinical models of insulin,resistance, ...
Other Medicine Technology:Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis 2Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis 3Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis 4CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of,Action for Ranexa 2CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of,Action for Ranexa 3
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
Medicine Products: